<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; containment</title>
	<atom:link href="http://www.tapanray.in/tag/containment/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Is The Global Generic Drug Market Slowing Down?</title>
		<link>http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-the-global-generic-drug-market-slowing-down</link>
		<comments>http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/#comments</comments>
		<pubDate>Sun, 04 Jun 2017 23:55:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[containment]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[down]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[elf]]></category>
		<category><![CDATA[expiration]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[hikes]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inflicted]]></category>
		<category><![CDATA[injury]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[murmurs]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[slowing]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trend]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8258</guid>
		<description><![CDATA[Driven by a strong environmental headwind, both within and outside the country, several pharma companies in India have recently started raising a red flag on their future earning guidance for the stock market, though citing quite different reasons altogether. Quoting &#8230; <a href="http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Leveraging 3D Printing In Pharma, For Cost Containment And Patient-Centricity</title>
		<link>http://www.tapanray.in/leveraging-3d-printing-in-pharma-for-cost-containment-and-patient-centricity/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=leveraging-3d-printing-in-pharma-for-cost-containment-and-patient-centricity</link>
		<comments>http://www.tapanray.in/leveraging-3d-printing-in-pharma-for-cost-containment-and-patient-centricity/#comments</comments>
		<pubDate>Mon, 06 Jun 2016 00:00:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[containment]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Patient-Centricity]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[printing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[role]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7662</guid>
		<description><![CDATA[Today, although a number of new and state of the art drugs is regularly being developed, and brought to the market at a reasonably rapid pace, their access to the majority of the global population has still remained a huge &#8230; <a href="http://www.tapanray.in/leveraging-3d-printing-in-pharma-for-cost-containment-and-patient-centricity/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/leveraging-3d-printing-in-pharma-for-cost-containment-and-patient-centricity/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Explore the Emerging Markets with the &#8216;Wings of Courage&#8217;.</title>
		<link>http://www.tapanray.in/explore-the-emerging-markets-with-the-wings-of-courage/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=explore-the-emerging-markets-with-the-wings-of-courage</link>
		<comments>http://www.tapanray.in/explore-the-emerging-markets-with-the-wings-of-courage/#comments</comments>
		<pubDate>Mon, 07 Mar 2011 00:30:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[cliff]]></category>
		<category><![CDATA[containment]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Courage]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[Explore]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Wings]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=293</guid>
		<description><![CDATA[Overall growth rate of the global pharmaceutical industry is currently hovering around 5%. Similar situation has been prevailing since last several years. There is no indication of acceleration of growth rate from any of the top 3 regions of the &#8230; <a href="http://www.tapanray.in/explore-the-emerging-markets-with-the-wings-of-courage/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/explore-the-emerging-markets-with-the-wings-of-courage/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Emerging markets and a robust oncology portfolio expected to be the future growth engine of the global pharmaceutical industry&#8230; but not without associated pricing pressures.</title>
		<link>http://www.tapanray.in/emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures</link>
		<comments>http://www.tapanray.in/emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures/#comments</comments>
		<pubDate>Thu, 08 Oct 2009 01:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[associated]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[But]]></category>
		<category><![CDATA[cliff]]></category>
		<category><![CDATA[containment]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[engine]]></category>
		<category><![CDATA[expected]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[portfolio]]></category>
		<category><![CDATA[pressures]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Robust]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[without]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=760</guid>
		<description><![CDATA[When the growth rate of the developed markets of the global pharmaceutical industry started slowing down along with the declining R&#38;D productivity, the emerging markets were identified as the new ‘El-Dorado’ by the global players. At the same time, new &#8230; <a href="http://www.tapanray.in/emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
